Monitor for next clinical milestones such as IND filing or Phase 1 initiation. The preclinical data supports the platform but is early-stage; stock movement likely limited until human data is available.
OPK drugs
OPK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $1.40entry
- T+1 · 5mo ago −0.71%α −0.12% · $1.39
- T+5 · 5mo ago +2.14%α +3.53% · $1.43
- T+20 · 4mo ago −12.14%α −11.39% · $1.23
- T+60 · 2mo ago +10.00%α +9.00% · $1.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OPKO Health presented preclinical data for OPK8801001, a long-acting hGH receptor antagonist for acromegaly, at ENDO 2026. In vitro data showed 20-fold greater potency than Pegvisomant, and in vivo data demonstrated dose-dependent IGF-1 suppression, suggesting potential for weekly dosing. However, these are early preclinical results with no clinical or regulatory milestones, limiting near-term impact.
Key Facts
- OPK8801001 is a novel long-acting hGH receptor antagonist for acromegaly.
- In vitro data showed approximately 20-fold greater potency than Pegvisomant.
- In vivo data demonstrated robust, dose-dependent, sustained suppression of IGF-1.
- Preclinical findings suggest potential for a once-weekly treatment alternative to daily therapies.
- Data presented at ENDO 2026, the Endocrine Society's annual meeting.
Financial Impact
No financial data provided; preclinical stage with no revenue impact.
Risk Factors
- Preclinical results may not translate to clinical efficacy or safety.
- Competition from existing acromegaly therapies (e.g., Pegvisomant, somatostatin analogs).
- Regulatory and development risks for a novel biologic candidate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311726 |
Track record
10 reports on OPK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $1.75 Now $1.62 −7.43% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 6/10 No price data
- Oct 15, 20264w ago 8-K Bullish 7/10 Entry $1.53 to $1.68 Now $1.62 +5.88% ▲ +9.80% +10.97% vs SPY
- Jul 27, 202616w ago 8-K Mixed 5/10 Entry $1.65 to $1.49 Now $1.62 −1.82% ▼ −9.70% −13.08% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $1.17 to $1.46 Now $1.62 +38.46% ▲ +24.79% +21.48% vs SPY
- Jun 15, 202622w ago Press Release Neutral 3/10 Viewing Entry $1.40 to $1.23 Now $1.62 +15.71% ▼ −12.14% −11.39% vs SPY
- May 15, 202626w ago DEFA14A Neutral 4/10 Entry $1.13 to $1.39 Now $1.62 +43.36% ▲ +23.01% +21.43% vs SPY
- Apr 30, 202628w ago Press Release Neutral 4/10 Entry $1.13 to $1.43 Now $1.62 +43.36% ▲ +26.55% +21.58% vs SPY
- Apr 22, 202629w ago Press Release Bullish 7/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
- Apr 21, 202629w ago Press Release Neutral 1/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers